A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Anticancer Research Année : 2024

A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects.

Malika Sebbah-Louriki
  • Fonction : Auteur
BM Colombo
Driss El Manouni
  • Fonction : Auteur
Antoine Martin
  • Fonction : Auteur
Jean-Loup Salzmann
  • Fonction : Auteur
Yves Leroux
  • Fonction : Auteur
Gérard Perret
  • Fonction : Auteur
Michel Crépin
  • Fonction : Auteur

Résumé

Sodium phenylacetate (NaPa) and some bisphosphonates demonstrated antiproliferative and proapoptotic properties against cancer. We have previously shown that NaPa inhibited cell proliferation of MCF7-ras tumor breast cells both in vitro and in vivo. On the other hand, bisphosphonate activities have only been demonstrated in vitro. Here we evaluated the antitumor effects of a new bisphosphonate, the phenylacetate-bisphosphonate (PaBp), on human breast cancer MCF7 and MCF7-ras cell lines, both in vitro and in vivo. To our knowledge, this is the first report indicating the use of a bisphosphonate derivative as a powerful cytostatic and cytotoxic agent, with proapoptotic and antiangiogenic properties on human breast cancer cells lines, with no animal toxicity.
Fichier non déposé

Dates et versions

hal-04393069 , version 1 (14-01-2024)

Identifiants

  • HAL Id : hal-04393069 , version 1
  • PUBMED : 12553014

Citer

Malika Sebbah-Louriki, BM Colombo, Driss El Manouni, Antoine Martin, Jean-Loup Salzmann, et al.. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects.. Anticancer Research, 2024, 22 (6C), pp.3925-31. ⟨hal-04393069⟩
3 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More